FDA’s Generic Regulatory Science Plan Taking Broad-brush Approach So Far
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency lists five topics for industry and stakeholders to focus on during a June 21 meeting on what its fiscal year 2014 priorities should be; among issues for consideration are prioritizing projects based on public health impact and identifying challenges that limit the availability of generic drugs.
You may also be interested in...
ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics
One project will look at tablet size, odor and other characteristics that in the past have been a source of public complaints about generics.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.